Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

Keppel Pacific Oak US REIT / Equity Capital Markets

<p>Keppel-KBS US REIT (KORE) is raising USD448m in its listing of US-based commercial REIT. Fellow insight provider <a href="https://www.smartkarma.com/profiles/1787" target="_blank" data-smartkarma-citation="accounts:1787">Will Tan, CAIA</a> has provided an excellent preview of the deal <a href="https://www.smartkarma.com/insights/keppel-kbs-us-reit-more-of-the-same-in-a-peaking-phase" target="_blank">here</a>. In this insight, we will continue from his effort, look at more details of the deal and score the deal in our ECM Framework. </p><div><h2>Deal and framework score overview</h2></div><p>The embed below is from our IPO tool, which has been designed to provide you with timely information on all IPO related events (Book open/closing, listing…</p>

Keppel-KBS US REIT (KORE) is raising USD448m in its listing of US-based commercial REIT. Fellow insight provider Will Tan, CAIA has provided an excellent preview of the deal here. In this insight, we will continue from his effort, look at more details of the deal and score the deal in our ECM Framework. Deal and framework score overviewThe embed below is from our IPO tool, which has been designed to provide you with timely information on all IPO related events (Book open/closing, listing…

Keppel-KBS US REIT IPO: Looks Cheap but Asset Mix Matters

Real Estate, General Equities

Will Tan

<p>As reported in the media recently, a Keppel KBS JV is targeting to list a US office REIT in Singapore later this year. If successfully listed this would be the second US office S-REIT following Manulife US REIT already listed in May 2016. In this note, pending more details from the prospectus and pricing, we share some of our first impressions on this IPO deal covering the portfolio and underlying US office market, quick comments on the Sponsor and relative comparison with listed peers / likely pricing. </p>

As reported in the media recently, a Keppel KBS JV is targeting to list a US office REIT in Singapore later this year. If successfully listed this would be the second US office S-REIT following Manulife US REIT already listed in May 2016. In this note, pending more details from the prospectus and pricing, we share some of our first impressions on this IPO deal covering the portfolio and underlying US office market, quick comments on the Sponsor and relative comparison with listed peers / likely pricing. 

Keppel-KBS US REIT: More of the Same in a Peaking Phase?

Singapore

Keppel Pacific Oak US REIT operates as a real estate investment trust with properties located in the United States. The Company invests in a diversified portfolio of income-producing commercial and real estate assets in key growth markets of the US.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Keppel Pacific Oak US REIT (KORE SP)

Keppel-KBS US REIT IPO: Looks Cheap but Asset Mix Matters

Keppel-KBS US REIT (KORE) is raising USD448m in its listing of US-based commercial REIT. Fellow insight provider Will Tan, CAIA has provided an...

Ke Yan, CFA, FRM

Keppel-KBS US REIT: More of the Same in a Peaking Phase?

As reported in the media recently, a Keppel KBS JV is targeting to list a US office REIT in Singapore later this year. If successfully listed this...

Will Tan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)